News
STAT+: Gilead drug prolongs survival of women with common form of breast cancer
Gilead Sciences said its cancer drug Trodelvy prolonged the survival of women with the most common form of breast cancer by just under 30%. […]
Biotech
News
STAT+: Third Rock Ventures plots next chapter after raising $1.1 billion fund
Third Rock Venture partners Abbie Celniker and Reid Huber spoke with STAT about their plans for investing their sixth and largest fund. The lion’s share of the $1.1 billion they… […]
News
STAT+: In study, Gilead’s Trodelvy shows modest benefit in breast cancer patients
The cancer drug Trodelvy reduced the risk of tumors progressing by 34% compared to chemotherapy in patients with the most common form of metastatic breast cancer. […]
News
STAT+: Theranos whistleblower Tyler Shultz on lessons learned, venture capital, and shutting down his own business
During the worst moments at Theranos, Tyler Shultz ran. To burn off the stress, he logged 20 miles at a clip in the mountains. And when that didn’t work, he… […]
News
STAT+: A ‘dark horse’ emerges in the DNA sequencing race, boasting a $100 genome
Bay Area biotech Ultima Genomics on Tuesday claimed that its technology can sequence a whole human genome for $100, making it a surprise player in the race to read DNA… […]
News
STAT+: Guardant accuses Illumina of ‘brazen’ attempt to quash competition in ongoing legal battle
Two months after being sued by Illumina over the alleged theft of trade secrets, Bay Area biotech Guardant Health fired back this week, rejecting the DNA sequencing giant’s claims and… […]
News
STAT+: Early cancer-detection market heats up as Guardant Health launches colon cancer test
Guardant Health announced the commercial launch of its early-detection colon cancer test, marking the latest twist in an escalating race to spot cancer sooner and more accurately. […]
News
STAT+: With milestones on the horizon, Guardant Health CEOs lay out their vision for cancer detection
Helmy Eltoukhy and AmirAli Talasaz, Guardant’s co-CEOs, discussed the company’s upcoming milestones, how they plan to separate themselves from the competition, and the future of liquid biopsies. […]
News
STAT+: What makes a biotech a biotech?
Historically, experts distinguished between biotech and pharma companies based on how a therapeutic was made. But the line’s gotten fuzzy, making it hard to measure things like how many companies… […]
